Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Developments and Clinical Progress
SLNO logo

Soleno Therapeutics Hits $98.7 Million in Revenue Following Breakthrough FDA Approval of VYKAT XR

SLNO10-QFiling Date: 11/4/2025
Soleno Therapeutics, Inc.
Description

What this story covers

Soleno Therapeutics transitioned to a commercial-stage company, generating $98.7 million in year-to-date revenue following FDA approval of VYKAT XR. With $556 million in liquid assets, the company is focused on U.S. expansion and European regulatory approval.

Story snapshot

CompanySoleno Therapeutics, Inc.
TickerSLNO
VariantStandard detailed
Duration11:48
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0001193125-25-264941
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-QView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in